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Abstract
This study investigated the impacts of renin–angiotensin system inhibitors (RASIs) on 2-year clinical outcomes in diabetes and
dyslipidemic acute myocardial infarction (AMI) patients after a successful percutaneous coronary intervention (PCI) using newer-
generation drug-eluting stents (DESs).
A total of 16,997 AMI patients were enrolled, and divided into four groups based on the presence or absence of diabetes and
dyslipidemia as follows: diabetes –/dyslipidemia –(group A, 11,132 patients), diabetes +/dyslipidemia – (group B, 3,860 patients),
diabetes –/dyslipidemia + (groupC, 1,328 patients), and diabetes +/dyslipidemia + (group D, 677 patients). The clinical endpoint was
the occurrence of major adverse cardiac events (MACEs), the composite of total death, recurrent myocardial infarction (re-MI), and
any repeat revascularization, including target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target
vessel revascularization (non-TVR).
After RASIs therapy, the cumulative incidences of MACEs (adjusted hazard ratio [aHR], 1.330; 95% confidence interval [CI], 1.022–
1.732; P= .034), any repeat revascularization (aHR, 1.584; 95%CI, 1.092–2.298; P= .015), TLR, and TVRwere significantly higher in
group B than group C. However, the cumulative incidences of all-cause death, cardiac death, re-MI, and non-TVR were similar in
groups B and C.Editor: Stefano Omboni.
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Kim et al. Medicine (2020) 99:30 MedicineIn this study, under the newer-generation DESs era, repeat revascularization rate reduction benefit of RASIs therapy in diabetic
AMI patients was lesser than that in dyslipidemic AMI patients. However, larger randomized controlled studies are needed to confirm
these results in the future.
Abbreviations: AMI = acute myocardial infarction, CAG = coronary angiography, DES = drug-eluting stents, KAMIR = Korea
Acute Myocardial Infarction Registry, MACEs = major adverse cardiac events, NSTEMI = non-ST-segment elevation myocardial
infarction, PCI = percutaneous coronary intervention, STEMI = ST-segment elevation myocardial infarction, TLR = target lesion
revascularization, TVR = target vessel revascularization.
Keywords: diabetes, dyslipidemia, renin–angiotensin system1. Introduction
Current guidelines recommend the use of angiotensin converting
enzyme inhibitors (ACEIs) in patients with ST-segment elevation
myocardial infarction (STEMI) and non-STEMI (NSTEMI).[1–4]
Additionally, angiotensin II type I (AT1) receptor blockers
(ARBs) are ACEIs alternatives for STEMI and NSTEMI patients
intolerant to ACEIs.[1–4] Renin–angiotensin system inhibitors
(RASIs) have been proven to ameliorate cardiovascular events via
improving endothelial function, cardiovascular remodeling, and
atherosclerosis progression.[5,6] Additionally, possible mecha-
nisms for the beneficial role of RASIs in diabetes progression
prevention have been suggested,[7,8] and according to these
studies, the main roles of RASIs in diabetes patients were
associated with insulin sensitivity improvement or insulin
secretion enhancement.[9,10] Recent meta-analysis reported that
ACEIs and ARBs have comparable effects on major cardiovas-
cular and renal outcomes (odds ratio, 1.10; 95% confidence
interval [CI], 0.90–1.40).[11] Anigotensin II has been shown to
indirectly induce differentiation of adipocyte precursors into
mature fat cell.[12] Angiotensin II further increases lipogenesis
and trigyceride content in the adipocytes by increasing fatty acid
synthase and glycerol-3-phosphate dehydrogenase.[13] Some
previous studies[14–16] have suggested that overexpressed AT1
receptors, as well as an increased affinity of such receptors for
circulating and locally released angiotensin II, are present in
hypercholesterolemia patients, and that ACEIs and ARBs inhibit
the production of angiotensin II or their binding to AT1 receptors
in these patients. However, published data that focuses on the
comparative beneficial effects of RASIs in diabetes and
dyslipidemia, especially in the acute myocardial infarction
(AMI) milieu, is limited. Hence, this study, which aimed at
investigating the impacts of RASIs on the 2-year clinical
outcomes in diabetic and dyslipidemic AMI patients who had
undergone a successful percutaneous coronary intervention (PCI)
using newer-generation drug-eluting stents (DESs), was con-
ducted.2. Methods
2.1. Study population
The data used for this study was obtained from the Korea AMI
Registry (KAMIR).[17] A total of 45,843 AMI patients who
underwent successful PCI between November 2005 and June
2015 were eligible. Patients with the following characteristics
were excluded: deployed bare-metal stents (n=2,099, 4.6%),
deployed first-generation DESs (n=9,967, 21.7%), RASIs were
not prescribed (n=4,346, 9.5%), incomplete laboratory results
(n=10,050, 21.9%), and lost to follow-up (n=2,384, 5.2%).2
Finally, a total of 16,997 AMI patients who had undergone
successful PCI with the use of newer-generation DESs, including
zotarolimus-eluting stent, everolimus-eluting stent, and biolimus-
eluting stent were enrolled. Among them, 11,132 (65.5%) were
classified as group A (diabetes and dyslipidemia negative group),
3,860 (22.7%) as group B (diabetes only group, i.e., diabetes
positive and dyslipidemia negative), 1,328 (7.8%) as group C
(dyslipidemia only group, i.e., diabetes negative and dyslipidemia
positive), and the remaining 677 (4.0%) as group D (diabetes and
dyslipidemia positive) (Fig. 1). The KAMIR is a nationwide,
prospective, observational on-line registry in South Korea,
established in November 2005. All data collection was done
using a web-based case report form at each participating center
and details of the registry can be found at the KAMIR website
(http://www.kamir.or.kr). This study protocol was approved by
the ethics committee at each participating center and the
Chonnam National University Hospital Institutional Review
Board (IRB) ethics committee (CNUH-2011-172) according to
the ethical guidelines of the 1975 Declaration of Helsinki. All the
16,997 included patients provided written informed consent
prior to enrollment, and also completed a 2-year clinical follow-
up by face-to-face interviews, phone calls, or chart review.
2.2. Percutaneous coronary intervention and medical
treatments
In accordance with general guidelines,[18] coronary angiography
and PCI were performed via the femoral or the radial artery, and
before PCI, all the patients were administered loading doses of
aspirin (200–300mg) and clopidogrel (300–600mg) when
available, or alternatively ticagrelor (180mg) or prasugrel (60
mg). The total duration of dual antiplatelet therapy (DAPT),
which is a combination of aspirin (100mg/day) with clopidogrel
(75mg/day), ticagrelor (90mg twice a day), or prasugrel (5–10
mg/day), was recommended for more than 12 months to patients
who had undergone PCI. The administration of triple antiplatelet
therapy (TAPT; 100mg of cilostazol administered twice a day in
addition to DAPT), was at the discretion of the individual
operators.2.3. Study definitions and endpoints
In this study, the presence of dyslipidemia was defined as a
positive dyslipidemia history, regardless of the presence or
absence of the administration of lipid-lowering agents, or the
administration of lipid-lowering agents, regardless of the
presence or absence of a dyslipidemia history.[19] In addition,
patients who neither had a history of dyslipidemia nor received
lipid-lowering agents, but had laboratory results that were
A total of 45843 AMI patients who underwent successful PCI in the KAMIR 
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Figure 1. Flow chart.
Kim et al. Medicine (2020) 99:30 www.md-journal.comcompatible with the dyslipidemia diagnostic criteria, were
considered dyslipidemic in this study. Given that the definition
of dyslipidemia varies based on the guidelines used, as well as on
ethnicity,[20–22] dyslipidemia was defined in accordance with the
Asian guideline,[23] that is, patients whose 12h fasting serum low-
density lipoprotein cholesterol concentrations were ≥140mg/dL,
high-density lipoprotein–cholesterol concentrations were <40
mg/dL, and triglyceride (TG) concentrations were ≥150mg/dL.
Diabetes was defined by treatment with glucose-lowering
medication, ≥6.5% glycosylated hemoglobin, fasting serum
glucose ≥126mg/dL, or non-fasting serum glucose ≥200mg/
dL.[24] If the admission electrocardiogram of patients who had
ongoing chest pain showed ST-segment elevations in at least 2
contiguous leads of ≥2mm (0.2mV) in men or ≥1.5mm (0.15
mV) in women in leads V2 to V3 and/or ≥1mm (0.1mV) in other
contiguous chest leads or limb leads, or new onset left bundle
branch block, then the patients were considered to be suffering
from ST-segment elevation myocardial infarction (STEMI).[2] If
they showed absence of persistent ST-segment elevation with
increased cardiac biomarkers, and the clinical context was
appropriate, the patients were considered as NSTEMI.[4] The
major clinical endpoint was the occurrence of major adverse
cardiac events (MACEs), defined as all-cause death, recurrent
myocardial infarction (re-MI), any repeat coronary revasculari-
zation, including target lesion revascularization (TLR), target
vessel revascularization (TVR), and non-TVR during the follow-
up period. All-cause death was classified as cardiac (CD) or non-
cardiac death. Re-MI was defined as the presence of clinical
symptoms, electrocardiographic changes, or abnormal MI
imaging findings, combined with an increase in the creatine
kinase myocardial band (CK-MB) fraction above the upper
normal limits or an increase in troponin-T/troponin-I to greater
than the 99th percentile of the upper normal limit, during the
follow-up period.[2] TLR was defined as the revascularization of
the target lesion due to restenosis or re-occlusion within the stent
or 5mm in and adjacent to the distal or proximal segment. TVR3
was defined as the revascularization of the target vessel or any
segment of the coronary artery containing the target lesion. Non-
TVR was defined as the revascularization of any segment of the
non-target coronary artery.2.4. Statistical analysis
All statistical analyses were performed using SPSS software v20
(IBM; Armonk, NY). Differences in the continuous variables of
the four groups were evaluated using analysis of variance
(ANOVA) or the Jonckheere–Terpstra test, and a post hoc
analysis was performed using the Hochberg test or Dunnett-T3
test; data are presented as means ± standard deviation (SD). For
discrete variables, differences between two of the four groups
were analyzed using the x2 test or Fisher’s exact test, as deemed
appropriate, and data are presented as counts and percentages.
During the multivariable Cox proportional hazards regression
analysis, the confounding baseline covariates were selected if they
were significantly different (P< .001) among the four groups, or
had predictive values, which are listed as follows: age, gender
(men), left ventricular ejection fraction (LVEF), body mass index,
diastolic blood pressure, STEMI, NSTEMI, hypertension,
previous myocardial infarction, previous PCI, previous coronary
artery bypass graft, previous cerebrovascular accident, previous
heart failure, current smoker, peak CK-MB, serum glucose,
hemoglobin A1c, N-terminal pro-brain natriuretic peptide,
serum creatinine, total cholesterol, triglyceride, low-density
lipoprotein–cholesterol, high-density lipoprotein–cholesterol,
cilostazole, calcium channel blocker, lipid lowering agent, left
anterior descending coronary artery—infarct-related artery, right
coronary artery-treated vessel, 1-vessel disease, 3-vessel disease,
multi-vessel disease, stent diameter, stent length, and number of
stents. Various clinical outcomes were estimated using the
Kaplan–Meier curve analysis, and group differences were
compared using the log-rank test. Two-tailed P< .05 was
considered statistically significant.
Table 1
















Men, n (%) 12,693 (74.7) 8597 (77.2) 2602 (67.4) 1018 (76.7) 476 (70.3) <.001
Age (years) 62.9±12.4 62.3±12.8 65.7±11.0 60.0±11.9 63.3±11.2 <.001
LVEF (%) 52.7±10.9 53.0±10.6 51.3±11.6 53.9±10.4 52.4±11.2 <.001
<50%, n (%) 6233 (36.7) 3998 (35.9) 1579 (40.9) 415 (31.3) 241 (35.6) <.001
BMI (kg/m2) 24.2±3.2 24.1±3.2 24.2±3.1 24.9±3.3 24.8±3.0 <.001
Systolic blood pressure (mmHg) 132.0±27.5 131.8±27.3 131.4±28.0 133.7±30.0 135.0±28.1 .002
Diastolic blood pressure (mmHg) 80.1±16.3 80.5±16.5 78.5±15.8 81.2±16.2 79.4±16.2 <.001
Cardiogenic shock, n (%) 627 (3.7) 384 (3.4) 167 (4.3) 51 (3.8) 25 (3.7) .098
STEMI, n (%) 9479 (55.8) 6495 (58.3) 1950 (50.5) 725 (54.6) 309 (45.6) <.001
Primary PCI, n (%) 9084 (95.8) 6244 (96.1) 1863 (95.5) 686 (94.6) 291 (94.2) .082
NSTEMI, n (%) 7518 (44.2) 4637 (41.7) 1910 (49.5) 603 (45.4) 368 (54.8) <.001
CPR on admission, n (%) 490 (2.9) 322 (2.9) 111 (2.9) 37 (2.8) 20 (3.0) .996
Hypertension, n (%) 8471 (49.8) 4673 (42.0) 2547 (66.0) 772 (58.1) 479 (70.8) <.001
Previous MI, n (%) 635 (3.7) 281 (2.5) 212 (5.5) 83 (6.3) 59 (8.7) <.001
Previous PCI, n (%) 1027 (6.0) 465 (4.2) 311 (8.1) 141 (10.6) 110 (16.2) <.001
Previous CABG, n (%) 74 (0.4) 25 (0.2) 35 (0.9) 8 (0.6) 6 (0.9) <.001
Previous CVA, n (%) 995 (5.9) 532 (4.8) 314 (8.1) 82 (6.2) 67 (9.9) <.001
Previous heart failure, n (%) 174 (1.0) 77 (0.7) 62 (1.6) 19 (1.4) 16 (2.4) <.001
Current smokers, n (%) 7389 (43.5) 5216 (46.9) 1336 (34.6) 583 (43.9) 254 (37.5) <.001
Peak CK-MB (mg/dL) 122.9±197.8 134.9±202.6 95.2±199.0 122.8±176.6 83.2±110.1 <.001
Peak troponin-I (ng/mL) 43.4±117.0 44.2±104.0 42.5±139.8 44.7±159.1 32.4±56.9 .140
Serum glucose (mg/dL) 166.6±76.1 146.1±52.9 227.0±99.6 142.3±48.7 210.0±87.1 <.001
Hemoglobin A1c (ng/dL) 6.58±2.12 6.0±1.92 7.76±2.23 5.95±0.92 7.67±1.58 <.001
NT-ProBNP (pg/mL) 1689.4±4497.8 1295.8±3581.4 2937.2±6366.5 899.6±2766.2 2348.3±5817.4 <.001
High-sensitivity CRP (mg/dL) 8.85±49.4 8.84±51.0 9.37±45.6 6.69±45.1 10.6±52.2 .020
Serum creatinine (mg/L) 1.07±1.02 1.00±0.93 1.22±1.22 1.02±1.01 1.20±1.12 <.001
Total cholesterol (mg/dL) 184.2±45.2 187.2±42.5 174.2±47.5 194.2±50.4 171.4±51.7 <.001
Triglyceride (mg/L) 137.4±113.3 133.1±111.2 140.3±118.4 155.0±111.8 156.1±115.2 <.001
HDL cholesterol (mg/L) 43.5±15.1 44.1±15.8 41.6±13.3 44.1±14.8 41.4±11.2 <.001
LDL cholesterol (mg/L) 116.2±40.5 119.3±41.0 107.0±36.4 123.2±42.9 101.4±38.2 <.001
Discharge medications, n (%)
Aspirin, n (%) 16‘,900 (99.4) 11,063 (99.4) 3838 (99.4) 1324 (99.7) 675 (99.7) .380
Clopidogrel, n (%) 14,689 (86.4) 9587 (86.1) 3358 (87.0) 1138 (85.7) 606 (89.5) .045
Ticagrelor, n (%) 1354 (8.0) 910 (8.2) 290 (7.5) 114 (8.6) 40 (5.9) .096
Prasugrel, n (%) 789 (4.6) 538 (4.8) 159 (4.1) 68 (5.1) 24 (3.5) .120
Cilostazole, n (%) 3292 (19.4) 2048 (18.4) 846 (21.9) 255 (19.2) 143 (21.1) <.001
BB, n (%) 14,972 (88.1) 9801 (88.0) 3383 (87.6) 1181 (88.9) 607 (89.7) .355
CCB, n (%) 986 (5.8) 537 (4.8) 273 (7.1) 95 (7.2) 81 (12.0) <.001
Lipid lowering agents, n (%) 14,908 (87.7) 9787 (87.9) 3310 (85.8) 1215 (91.5) 596 (88.0) <.001
Diabetes management
Diet, n (%) 379 (9.8) 57 (8.4)
Oral agent, n (%) 3147 (81.5) 561 (82.9)
Insulin, n (%) 267 (6.9) 52 (7.7)
Untreated, n (%) 67 (0.2) 7 (0.1)
Infarct-related artery (IRA)
Left main, n (%) 297 (1.7) 181 (1.6) 77 (2.0) 21 (1.6) 18 (2.7) .121
Left anterior descending, n (%) 8161 (48.0) 5472 (49.2) 1783 (46.2) 616 (46.4) 290 (42.8) <.001
Left circumflex, n (%) 2849 (16.8) 1857 (16.7) 632 (16.4) 234 (17.6) 126 (18.6) .418
Right coronary artery, n (%) 5690 (33.5) 3622 (32.5) 1368 (35.4) 457 (34.4) 243 (35.9) .004
Treated vessel
Left main, n (%) 471 (2.8) 285 (2.6) 125 (3.2) 38 (2.9) 23 (3.4) .112
Left anterior descending, n (%) 9277 (57.5) 6394 (57.4) 2267 (58.7) 743 (55.9) 373 (55.1) .150
Left circumflex, n (%) 4416 (26.0) 2798 (25.1) 1060 (27.5) 372 (28.0) 186 (27.5) .007
Right coronary artery, n (%) 6780 (39.9) 4283 (38.5) 1665 (43.1) 544 (41.0) 288 (42.5) <.001
ACC/AHA lesion type
Type B1, n (%) 2420 (14.2) 1642 (14.8) 499 (12.9) 184 (13.9) 95 (14.0) .046
Type B2, n (%) 5704 (33.6) 3738 (33.6) 1353 (35.1) 408 (30.7) 205 (30.3) .008
Type C, n (%) 7350 (43.2) 4737 (42.6) 1697 (44.0) 616 (46.4) 300 (44.3) .035
Type B2/C, n (%) 13,054 (76.8) 8475 (76.2) 3050 (79.0) 1024 (77.1) 505 (74.6) .002
(continued )



















Extent of coronary artery disease
1-vessel, n (%) 8488 (49.9) 5912 (53.1) 1623 (42.0) 674 (50.8) 279 (41.2) <.001
2-vessel, n (%) 5260 (30.9) 3364 (30.2) 1280 (33.2) 410 (30.9) 206 (30.4) .008
≥3-vessel, n (%) 3249 (19.1) 1856 (16.7) 957 (24.8) 244 (18.4) 192 (28.4) <.001
MVD, n (%) 8509 (50.1) 5220 (46.9) 2237 (58.0) 654 (49.2) 398 (58.8) <.001
IVUS, n (%) 3254 (19.1) 2132 (19.2) 684 (17.7) 286 (21.5) 152 (22.5) .002
OCT, n (%) 103 (0.6) 70 (0.6) 18 (0.5) 8 (0.6) 7 (1.0) .333
FFR, n (%) 182 (1.1) 130 (1.2) 40 (1.0) 8 (0.6) 4 (0.6) .154
Types of stent
ZES, n (%) 5654 (33.3) 3688 (33.1) 1251 (32.4) 495 (37.3) 220 (32.5) .011
EES, n (%) 7696 (45.3) 4947 (44.4) 1829 (47.4) 600 (45.2) 320 (47.3) .011
BES, n (%) 2208 (13.0) 1518 (13.6) 466 (12.1) 138 (10.4) 86 (12.7) .002
Stent diameter (mm) 3.15±0.43 3.17±0.43 3.10±0.42 3.15±0.42 3.09±0.44 <.001
Stent length (mm) 26.6±11.1 26.3±10.8 27.5±12.0 26.7±10.6 26.9±10.7 <.001
Number of stent 1.47±0.78 1.43±0.75 1.56±0.83 1.51±0.83 1.52±0.82 <.001
Values are means±SD or numbers and percentages. The P value for continuous data was obtained from the analysis of variance or the Jonckheere–Terpstra test, and post hoc analysis was done using the
Hochberg test or Dunnett-T3 test. The P value for categorical data was obtained from the chi-square or the Fisher’s exact test.
ACC/AHA=American College of Cardiology/American Heart Association, BB=beta-blockers, BES=biolimus-eluting stents, BMI=body mass index, CABG= coronary artery bypass graft, CCB= calcium channel
blockers, CK-MB= creatine kinase myocardial band, CRP=C-reactive protein, CVA= cerebrovascular accident, EES= everolimus-eluting stents, FFR= fractional flow reserve, HDL=high-density lipoprotein,
IVUS= intravascular ultrasound, LDL= low-density lipoprotein, LVEF= left ventricular ejection fraction, MI=myocardial infarction, MVD=multivessel disease, NSTEMI=non-STEMI, NT-ProBNP=N-terminal
pro-brain natriuretic peptide, OCT= optical coherence tomography, PCI=percutaneous coronary intervention, STEMI=ST-segment elevation myocardial infarction, ZES= zotarolimus-eluting stents.
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3.1. Baseline clinical, angiographic and procedural
characteristics
Table 1 shows the baseline, laboratory, angiographic, and
procedural characteristics of the study population, which had a
mean age of 62.9±12.4 years, and a mean left ventricular
ejection fraction (LVEF) value of 52.7±10.9%. The number of
men among the enrolled patients was highest in group A (77.2%).
The observed number of patients showing cardiovascular risk
factors such as hypertension, ≥3-vessel disease, and previous MI,
PCI, cerebrovascular accident, and heart failure, were highest in
group D. Blood glucose, hemoglobin A1c, N-terminal pro-brain
natriuretic peptide, and creatinine levels were highest in group B.
In group C, blood total cholesterol and low-density lipoprotein–
cholesterol levels, as well as the prescription rate of lipid lowering
agents were the highest. However, the number of STEMI cases,
current smokers, and the mean serum peak CK-MB value were
highest in group A. The left main coronary artery and rightTable 2










MACEs 1118 (6.6) 633 (5.7) 3
All-cause death, n (%) 399 (2.3) 213 (1.9) 1
Cardiac death 278 (1.6) 153 (1.4)
Re-MI, n (%) 262 (1.5) 146 (1.3)
Any repeat revascularization 569 (3.3) 326 (2.9) 1
TLR 157 (0.9) 83 (0.7)
TVR 340 (2.0) 188 (1.7) 1
Non-TVR 239 (1.4) 145 (1.3)
MACEs=major adverse cardiac events, Re-MI= recurrent myocardial infarction, TLR= target lesion rev
5
coronary artery were the most frequent infarct-related artery in
group D, while left anterior descending coronary artery was the
most frequent infarct-related artery in group A. The numbers of
American College of Cardiology/American Heart Association
(ACC/AHA) type B2 and ACC/AHA type B2/C lesions were
highest in group B, while the number of ACC/AHA type C lesions
was highest in group C. During the PCI, the use of intravascular
ultrasound was most frequent in group D. The diameter of the
deployed stent was largest in group A, while its total length was
longest in group B.
3.2. Clinical outcomes
The cumulative frequencies of MACEs, all-cause death, CD, any
repeat revascularization, TLR, and TVR over the 2-year follow-
up period are summarized in Table 2. Before adjustment, the
cumulative incidences of MACEs, CD, any repeat revasculariza-
tion, TLR, and TVR were highest in group D, while the
cumulative incidence of all-cause death was highest in group B.









42 (8.9) 78 (5.9) 65 (9.6) <.001
40 (3.6) 26 (2.0) 20 (3.0) <.001
85 (2.2) 23 (1.7) 17 (2.5) .001
79 (2.0) 17 (1.3) 20 (3.0) <.001
70 (4.4) 40 (3.0) 33 (4.9) <.001
55 (1.4) 7 (0.5) 12 (1.8) <.001
06 (2.7) 23 (1.7) 23 (3.4) <.001
66 (1.7) 18 (1.4) 10 (1.5) .323
ascularization, TVR= target vessel revascularization.
Table 3
Hazard ratio for 2-year major clinical outcomes.
Hazard ratio (95% CI) unadjusted P Event rates at 2 years
∗
(%) Log-rank Hazard ratio (95% CI) adjusted† P
MACEs
Group A vs 6.1
Group B 1.579 (1.385–1.801) <.001 9.6 <0.001 1.355 (1.176–1.562) <.001
Group C 1.032 (0.816–1.306) .790 6.3 0.790 1.034 (0.806–1.325) .795
Group D 1.730 (1.340–2.233) <.001 10.4 <0.001 1.499 (1.142–1.969) .004
Group B vs group C 1.531 (1.197–1.958) .001 0.001 1.330 (1.022–1.732) .034
Group B vs group D 1.096 (0.841–1.429) .496 0.496 1.104 (0.838–1.455) .483
Group C vs group D 1.675 (1.205–2.328) .002 0.002 1.429 (1.003–2.035) .048
All-cause death
Group A vs 2.0
Group B 1.907 (1.540–2.360) <.001 3.9 <0.001 1.476 (1.169–1.864) .001
Group C 1.024 (0.682–1.539) .908 2.0 0.908 1.198 (0.772–1.859) .421
Group D 1.555 (0.984–2.460) .059 3.1 0.057 1.481 (0.905–2.423) .118
Group B vs group C 1.862 (1.225–2.830) .004 0.003 1.248 (0.792–1.968) .340
Group B vs group D 1.224 (0.766–1.956) .397 0.396 1.137 (0.698–1.853) .607
Group C vs group D 1.515 (0.846–2.714) .162 0.158 1.194 (0.628–2.270) .588
Cardiac death
Group A vs 1.4
Group B 1.610 (1.235–2.098) <.001 2.4 <0.001 1.185 (0.889–1.578) .247
Group C 1.261 (0.814–1.955) .299 1.8 0.298 1.330 (0.825–2.144) .242
Group D 1.838 (1.114–3.034) .017 2.7 0.015 1.692 (0.997–2.871) .051
Group B vs group C 1.276 (0.805–2.023) .299 0.298 1.130 (0.681–1.875) .637
Group B vs group D 1.143 (0.679–1.924) .615 0.614 1.201 (0.703–2.051) .502
Group C vs group D 1.455 (0.777–2.724) .241 0.237 1.280 (0.648–2.528) .478
Re-MI
Group A vs 1.4
Group B 1.574 (1.197–2.069) .001 2.3 0.001 1.277 (0.954–1.710) .100
Group C 1.024 (0.620–1.692) .927 1.4 0.927 1.091 (0.654–1.820) .739
Group D 2.295 (1.438–3.662) <.001 3.3 <0.001 1.685 (1.017–2.792) .043
Group B vs group C 1.614 (0.956–2.726) .073 0.071 1.367 (0.796–2.349) .257
Group B vs group D 1.459 (0.893–2.382) .132 0.129 1.373 (0.822–2.293) .226
Group C vs group D 2.350 (1.231–4.486) .010 0.008 1.739 (0.878–3.445) .112
Any repeat revascularization
Group A vs 3.2
Group B 1.529 (1.270–1.840) <.001 4.9 <0.001 1.434 (1.176–1.749) <.001
Group C 1.027 (0.740–1.426) .874 3.4 0.874 1.091 (0.768–1.549) .627
Group D 1.699 (1.188–2.430) .004 5.4 0.003 1.457 (0.999–2.125) .051
Group B vs group C 1.490 (1.056–2.102) .023 0.022 1.584 (1.092–2.298) .015
Group B vs group D 1.111 (0.765–1.614) .579 0.579 1.021 (0.695–1.501) .915
Group C vs group D 1.656 (1.044–2.625) .032 0.030 1.555 (0.946–2.555) .082
TLR
Group A vs. 0.8
Group B 1.933 (1.375–2.717) <.001 1.6 <0.001 1.855 (1.282–2.685) .001
Group C 1.416 (0.655–3.062) .377 0.6 0.374 1.355 (0.618–2.969) .448
Group D 2.415 (1.319–4.425) .004 2.0 0.003 2.019 (1.057–3.856) .033
Group B vs group C 2.739 (1.247–6.015) .012 0.009 1.593 (1.072–2.341) .043
Group B vs group D 1.248 (0.669–2.331) .486 0.485 1.197 (0.632–2.269) .581
Group C vs group D 3.421 (1.347–8.690) .010 0.006 1.635 (0.995–2.978) .039
TVR
Group A vs. 1.9
Group B 1.648 (1.299–2.091) < .001 3.1 <0.001 1.556 (1.205–2.010) .001
Group C 1.025 (0.665–1.580) .911 1.9 0.911 1.099 (0.694–1.742) .686
Group D 2.050 (1.330–3.161) .001 3.8 0.001 1.651 (1.038–2.628) .038
Group B vs group C 1.610 (1.026–2.528) .038 0.037 1.670 (1.029–2.711) .034
Group B vs group D 1.242 (0.792–1.950) .345 0.344 1.118 (0.699–1.787) .642
Group C vs group D 1.999 (1.122–3.563) .119 0.117 1.780 (0.955–3.317) .069
Non-TVR
Group A vs. 1.4
Group B 1.328 (0.992–1.776) .056 1.9 0.056 1.235 (0.907–1.683) .180
Group C 1.040 (0.637–1.698) .875 1.5 0.875 1.084 (0.642–1.832) .762
Group D 1.147 (0.604–2.177) .675 1.6 0.675 1.072 (0.556–2.068) .835
Group B vs group C 1.275 (0.757–2.147) .361 0.360 1.369 (0.777–2.411) .277
Group B vs group D 1.154 (0.593–2.244) .673 0.672 1.181 (0.601–2.322) .630
Group C vs group D 1.105 (0.510–2.395) .799 0.799 1.126 (0.494–2.566) .778
BMI=body mass index, CABG= coronary artery bypass graft, CCB= calcium channel blocker, CI= confidence interval, CK-MB= creatine kinase myocardial band, CVA=cerebrovascular accidents, DBP=
diastolic blood pressure, HbA1c=hemoglobin A1c, HDL=high-density lipoprotein, HF=heart failure, IRA= infarct-related artery, LAD= left anterior descending coronary artery, LDL= low-density lipoprotein,
LVEF= left ventricular ejection fraction, MACEs=major adverse cardiac event, MI=myocardial infarction, NSTEMI=non-STEMI, NT-ProBNP=N-terminal pro-brain natriuretic peptide, PCI=percutaneous
coronary intervention, RCA= right coronary artery, Re-MI= recurrent myocardial infarction, STEMI=ST-segment elevation myocardial infarction, TLR= target lesion revascularization, TVR= target vessel
revascularization.
∗
Event rates at 2 years were calculated by Kaplan–Meyer analysis.
† Adjusted model includes age, gender (men), LVEF, BMI, DBP, STEMI, NSTEMI, hypertension, previous MI, previous PCI, previous CABG, previous CVA, previous HF, current smoker, peak CK-MB, serum glucose,
HbA1c, NT-ProBNP, serum creatinine, total cholesterol, triglyceride, LDL-cholesterol, HDL-cholesterol, cilostazole, CCB, lipid lowering agent, LAD-IRA, RCA-treated vessel, 1-vessel disease, ≥ 3-vessel disease,
stent diameter, stent length, number of stent.
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Figure 2. Kaplan–Meier curved analysis for MACEs (A), all-cause death (B), cardiac death (C), re-MI (D), any repeat revascularization (E), TLR (F), and TVR (G).
Kim et al. Medicine (2020) 99:30 www.md-journal.comgroups was similar before and after adjustment. Furthermore,
after adjustment, group B (9.6% vs 6.1%, Log-rank P< .001;
adjusted hazard ratio [aHR], 1.355; 95% CI, 1.176–1.562;
P< .001, Table 3 and Fig. 2) and D (10.4% vs 6.1%, Log-rank
P< .001; aHR, 1.499; 95% CI, 1.142–1.969; P= .004) showed
higher cumulative incidences ofMACEs compared with group A.
Additionally, the cumulative incidences of all-cause death (aHR,
1.476; 95% CI, 1.169–1.846; P= .001), any repeat revasculari-
zation (aHR, 1.434; 95% CI, 1.176–1.749; P< .001), TLR
(aHR, 1.855; 95% CI, 1.282–2.685; P= .001), and TVR (aHR,
1.556; 95% CI, 1.205–2.010; P= .001) in group B were
significantly higher than those in group A (Table 3 and
Fig. 2). Furthermore, the cumulative incidences of Re-MI
(aHR, 1.685; 95% CI, 1.107–2.792; P= .043), TLR (aHR,
2.019; 95% CI, 1.057–3.856; P= .033), and TVR (aHR, 1.651;
95% CI, 1.038–2.628; P= .038) in group D were significantly
higher than those in group A (Table 3). Comparing the MACEs
cumulative incidences of group B and C showed that it was7
significantly higher in group B than in group C (aHR, 1.330; 95%
CI, 1.022–1.732; P= .034). After adjustment, even though the
cumulative incidences of all-cause death, CD, and re-MI were
similar for group B andC, the cumulative incidences of any repeat
revascularization (aHR, 1.584; 95% CI, 1.092–2.298; P= .015),
TLR (aHR, 1.593; 95% CI, 1.072–2.341; P= .043), and TVR
(aHR, 1.670; 95% CI, 1.029–2.711; P= .034) were significantly
higher in group B compared with group C. Figure 3 shows
subgroup analysis for MACEs for groups B and C at 2 years.
Regarding men, decreased LVEF (<50%), NSTEMI, regardless
of presence or absence of hypertension, and the use of lipid
lowering agents, RASIs showed more beneficial effect on
reducing MACEs in the group C compared with the group B.
Additionally, old age (≥65 years), decreased LVEF (<50%),
hypertension, STEMI, cardiopulmonary resuscitation on admis-
sion, serum creatinine, multi-vessel disease, and the use of
intravascular ultrasound were independent MACEs predictors
(Table 4).
Figure 2. (Continued).
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The main findings of this study include:1. post RASIs therapy, the cumulative incidences of MACEs, any
repeat revascularization, TLR, and TVR were significantly
higher in group B than group C;2. the cumulative incidences of all-cause death, CD, re-MI, and
non-TVR were similar in group B and C;3. the cumulative incidences of MACEs, all-cause death, any
repeat revascularization, TLR, and TVR in group B were
significantly higher than those in group A;4. the cumulative incidences ofMACEs, re-MI, TLR, and TVR in
group D were significantly higher than those in group A; and5. old age (≥65 years), decreased LVEF (<50%), hypertension,
STEMI, cardiopulmonary resuscitation on admission, serum
creatinine, multi-vessel disease, and intravascular ultrasound
use were independent MACEs predictors.8
Kawasaki et al[25] demonstrated that ARBs improve diastolic
dysfunction in diabetic patients, at least via the attenuation of
myocardial fibrosis. Although dyslipidemia is a major determi-
nant of long-term clinical outcomes in AMI patients, many recent
studies have focused on high-dose statin therapy, rather than the
important role of RASI.[26,27] The SMILE (Survival of Myocar-
dial Infarction Long-term Evaluation) trial[28] and its post hoc
analysis[29] demonstrated that compared with the placebo and
normocholesterolemic group, the early treatment with zofenopril
was more effective in reducing morbidity and mortality in AMI
and hypercholesterolemia patients (relative risk reduction=43%,
P= .034). Despite these previous studies that have proven the
beneficial effects of RASIs in diabetes and dyslipidemia, there
exist limited comparative data on the long-term major clinical
outcomes of RASI therapy in diabetic and dyslipidemic AMI
patients. Thus, the main objective of this study was to compare












































































































































Figure 3. Subgroup analysis for MACEs between the group B and the group C at 2 years.
Kim et al. Medicine (2020) 99:30 www.md-journal.comonstrated that the cumulative incidences ofMACEs (aHR, 1.330;
95% CI, 1.022–1.732; P= .034), any repeat revascularization
(aHR, 1.584; 95% CI, 1.092–2.298; P= .015), TLR (aHR,
1.593; 95% CI, 1.072–2.341; P= .043), and TVR (aHR, 1.670;
95% CI, 1.029–2.711; P= .034) were significantly higher in
group B compared with group C in AMI patients who underwent
successful PCI with newer-generation DESs after RASIs therapy.
In Tables 2 and 3, the higher cumulative incidence of MACEs in
groups B (aHR, 1.355; 95% CI, 1.176–1.562; P< .001) and D
(aHR, 1.499; 95% CI, 1.142–1.969; P= .004) in comparison
with group A was expected. The potential mortality reduction
capability of RASIs in AMI patients had been reported in
previous studies,[6,30,31] and in the present study, RASIs therapy-
reduced mortality rates were similar in groups B and C (all-cause
death [aHR, 1.248; 95% CI, 0.792–1.968; P= .340] and CD
[aHR, 1.130; 95% CI, 0.681–1.875; P= .637]) indicating that
the results of this study are compatible with those of previous
studies.[6,30,31] Compared with non-diabetic patients, diabetes
appeared to increase the risk of TLR, TVR, and MACEs after
PCI, conferred a poorer clinical outcome, and was associated
with plaque growth and vascular instability.[32–34] The character-
istics of lesions in diabetic patients are known to be longer, and9
present in smaller vessels compared with non-diabetic
patients.[35] In the present study, the number of multi-vessel
disease cases (58.0% vs 49.2%, P< .001) and the total length of
the deployed stents (27.5±12.0mm vs 26.7±10.6mm, P= .018)
were significantly higher in group B than group C. Thus, these
baseline lesion characteristics may have contributed to the higher
cumulative incidences of any repeat revascularization, TLR, and
TVR observed in group B as compared to group C, after
multivariable analysis. Additionally, in this study, we tried to get
the results to reflect current “real-world” practice, which involves
the use of newer-generation DESs. Hence, patients who received
bare-metal stents or first-generation DESs were excluded.
Diabetes patients treated with first-generation DESs reportedly
showed higher rates of repeat revascularization compared with
non-diabetes patients (TLR [6.8% vs 4.6%, P= .0002] and TVR
[9.4% vs 6.2%, P< .0001]).[32] In the newer-generation DESs
era, the rate of recurrence of any repeat revascularization was
also significantly higher in diabetes patients (20.2% vs 12.7%,
P= .007).[36] Although the precise mechanisms of the observed
restenosis are not fully understood, some suggested mechanisms
include abnormal vascular wall response to the implanted stent
and smooth muscle cell proliferation.[37] In addition, Mizia-Stec
Table 4
Independent predictors for MACE at 2 years.
Unadjusted Adjusted
Variables HR (95% CI) P HR (95% CI) P
Age (≥65 years) 1.523 (1.353–1.713) <.001 1.257 (1.103–1.431) .001
Men 1.297 (1.141–1.473) <.001 1.094 (0.952–1.257) .207
LVEF (50%) 1.344 (1.194–1.513) <.001 1.291 (1.141–1.462) <.001
Hypertension 1.347 (1.197–1.516) <.001 1.194 (1.054–1.353) .005
STEMI 1.222 (1.087–1.374) .001 1.175 (1.037–1.332) .012
Cardiogenic shock 1.367 (1.043–1.793) .024 1.206 (0.910–1.599) .193
CPR on admission 2.302 (1.798–2.947) <.001 2.207 (1.711–2.846) <.001
Serum creatinine 1.089 (1.054–1.125) <.001 1.081 (1.044–1.121) <.001
ACC/AHA type B2/C lesion 1.172 (1.016–1.352) .029 1.077 (0.928–1.249) .329
MVD 1.796 (1.589–2.030) <.001 1.609 (1.406–1.843) <.001
Clopidogrel 1.078 (0.889–1.306) .445 1.053 (0.865–1.283) .607
Cilostazole 0.944 (0.814–1.094) .442 0.913 (0.785–1.063) .242
LAD (IRA) 0.994 (0.884–1.118) .921 1.073 (0.925–1.245) .352
RCA (treated vessel) 1.116 (0.991–1.256) .070 1.058 (0.906–1.236) .477
IVUS 1.319 (1.148–1.516) <.001 1.296 (1.123–1.494) <.001
Stent diameter (≥3mm) 1.149 (1.013–1.304) .031 1.073 (0.941–1.224) .291
Stent length (≥28mm) 1.276 (1.134–1.436) <.001 1.132 (1.000–1.280) .050
Number of stent 1.186 (1.110–1.268) <.001 1.009 (0.932–1.091) .829
ACC/AHA =American College of Cardiology/American Heart Association, CPR= cardiopulmonary resuscitation, HR=hazard ratio, IRA= infarct-related artery, IVUS= intravascular ultrasound, LAD= left anterior
descending coronary artery, LVEF= left ventricular ejection fraction, MACE=major adverse cardiac events, MVD=multivessel disease, RCA= right coronary artery, STEMI=ST-segment elevation myocardial
infarction.
Kim et al. Medicine (2020) 99:30 Medicineet al[38] suggested that in-stent coronary restenosis is associated
with impaired endothelial-dependent vasodilation rather than the
stent type used. Endothelial dysfunction is an important
cardiovascular risk factor, given that it is a critical factor in
the genesis of vascular disease.[39] Dyslipidemia is another well-
known factor, crucial for endothelial damage, and an important
predictor of atherosclerosis development.[40] The causes of
restenosis are complex, and include endothelial dysfunction,
thrombosis, proliferation of smooth muscle cells, vascular
remodeling, inflammatory reaction, and the release of various
cytokines.[41] Unfortunately, due to the complexity of these
causative factors involved in restenosis in diabetes and
dyslipidemia, the main cause of the different revascularization
rates in diabetes and dyslipidemia could not be narrowed down
to any one specific factor, in the present study.
Despite these limitations, the results of this study may provide
meaningful information that can help interventional cardiologists
better understand the important roles of RASIs with respect to
MACEs, any repeat revascularization, TLR, and TVR in diabetes
mellitus and dyslipidemia in AMI patients who have undergone a
successful PCI using newer-generation DESs.
The KAMIR is a nationwide, prospective, observational on-
line registry in South Korea since November 2005. More than 50
high-volume University or community hospitals with facilities for
primary PCI and onsite cardiac surgery participated in this study.
Therefore, we believe the study population of this study is
sufficiently large to provide meaningful results. Furthermore, the
results of this comparative study may persuade interventional
cardiologists of the different clinical impacts of RASIs between
diabetes and dyslipidemia with respect to long-term follow-up in
AMI patients after successful PCI with newer-generation DESs.
This study had some limitations. First, dyslipidemia was
defined according to the Asian guidelines, including the guide-
lines of the Japan Atherosclerosis Society,[23] whereas this
criterion may differ based on ethnicity or region. Second, there
was the possibility of sample selection bias, given that the total10numbers of diabetes and dyslipidemia patients in this study were
relatively lower compared with those in a previous trial.[42] This
selection bias may be related to the fact that many patients were
excluded using the exclusion criteria, which included the
deployment of first-generation DESs (n=9,967, 21.7%) and
incomplete laboratory results (n=10,050, 21.9%). Additionally,
in this registry cohort, the cumulative incidence of all-cause death
was higher in group B than group D (3.6% vs 3.0%, P= .381,
Table 2). Even though this difference was not statistically
significant but numerically different (aHR, 1.137; 95% CI,
0.698–1.853; P= .396, Table 3), it is hard to explain the exact
cause. It also may be associated with sample selection bias. Third,
there may be some under-reporting and/or missed data because
the study was a non-randomized study. Fourth, the study was
based on medications at discharge, and this registry data did not
include detailed or full data on the prescription doses, long-term
adherence, discontinuation, and drug-related adverse events.
Therefore, this might have been an important source of bias in
this study. Fifth, the achievement of the target blood cholesterol
level (i.e., low-density lipoprotein–cholesterol) was a very
important prognostic parameter in diabetes or dyslipidemia
patients during the follow-up period. However, in this KAMIR,
the follow-up data was not provided. Therefore, this might have
introduced a bias. Sixth, during the follow-up period, the patients
enrolled in groups B or C could have been transferred to group D.
However, this information could not be verified because of the
limitations of the registry data; thus, this could also act as a bias.
Seven, to strengthen the results of this study, multivariable
analyses were performed; however, the variables that were not
included in the data registry might have affected the study
outcome. Last, rise in blood pressure is closely linked to an
increase in measures of obesity, which, in turn, associated with an
increase insulin resistance and worsening of an atherogenic lipid
profile.[43] Therefore, arterial hypertension could influence our
results. However, in this study, we were more focused on the
comparative clinical outcomes between diabetes and dyslipide-
Kim et al. Medicine (2020) 99:30 www.md-journal.commia rather than arterial hypertension. This may be important
limitation in this study.
To conclude, in this study, under the newer-generation DESs
era, repeat revascularization rate reduction benefit of RASIs
therapy in diabetic AMI patients was lesser than that in
dyslipidemic AMI patients. However, larger randomized con-
trolled studies are needed to confirm these results in the future.Acknowledgments
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